All the news Showing 10 of 141 articles from: Nucleotide Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug Treatment Action Group / 25 July 2014 Gilead's Sovaldi soars with sales of $3.48 billion Pharma Times / 25 July 2014 A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi Reuters / 23 June 2014 NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C NICE press release / 16 June 2014 Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV Achillion press release / 10 June 2014 Sustained response to treatment reduces fatigue in people with hepatitis C Keith Alcorn / 30 May 2014 Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most concerning symptoms associated with chronic hepatitis C, according to research presented at the ... Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation Liz Highleyman / 29 May 2014 An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to ... Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed i-Base / 28 May 2014 Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4 Liz Highleyman / 28 May 2014 A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus genotype 4, though treatment for only 12 weeks was not as effective, according to a ... Impact of Food and Antacids on Levels of Ledipasvir and Sofosbuvir NATAP / 28 May 2014 ← Prev1...34567...15Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive